Parasites, Hosts and Diseases

The Korea Society for Parasitology and Tropical Medicine (대한기생충학·열대의학회)
권호 표지
DOI QR코드

DOI QR Code

$Fasciola$ $gigantica$ Fatty Acid Binding Protein (FABP) as a Prophylactic Agent against $Schistosoma$ $mansoni$ Infection in CD1 Mice

  • Aly, Ibrahim Rabia (Theodore Bilharz Research Institute) ;
  • Diab, M. (Theodore Bilharz Research Institute) ;
  • El-Amir, A.M. (Zoology Department, Faculty of Science, Cairo University) ;
  • Hendawy, M. (Theodore Bilharz Research Institute) ;
  • Kadry, S. (Zoology Department, Faculty of Science, Cairo University)
  • Received : 2011.09.04
  • Accepted : 2011.11.10
  • Published : 2012.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Although schistosomicidal drugs and other control measures exist, the advent of an efficacious vaccine remains the most potentially powerful means for controlling this disease. In this study, native fatty acid binding protein (FABP) from $Fasciola$ $gigantica$ was purified from the adult worm's crude extract by saturation with ammonium sulphate followed by separation on DEAE-Sephadex A-50 anion exchange chromatography and gel filtration using Sephacryl HR-100, respectively. CD1 mice were immunized with the purified, native $F.$ $gigantica$ FABP in Freund's adjuvant and challenged subcutaneously with 120 $Schistosoma$ $mansoni$ cercariae. Immunization of CD1 mice with $F.$ $gigantica$ FABP has induced heterologous protection against $S.$ $mansoni$, evidenced by the significant reduction in mean worm burden (72.3%), liver and intestinal egg counts (81.3% and 80.8%, respectively), and hepatic granuloma counts (42%). Also, it elicited mixed $IgG_1/IgG_{2b}$ immune responses with predominant $IgG_1$ isotype, suggesting that native $F.$ $gigantica$ FABP is mediated by a mixed Th1/Th2 response. However, it failed to induce any significant differences in the oogram pattern or in the mean granuloma diameter. This indicated that native $F.$ $gigantica$ FABP could be a promising vaccine candidate against $S.$ $mansoni$ infection.

Keywords

References

  1. King CH. Toward the elimination of schistosomiasis. N Engl J Med 2009; 360: 106-109. https://doi.org/10.1056/NEJMp0808041
  2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-425. https://doi.org/10.1016/S1473-3099(06)70521-7
  3. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003; 86: 125-139. https://doi.org/10.1016/S0001-706X(03)00029-9
  4. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21: 225-242. https://doi.org/10.1128/CMR.00046-07
  5. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005; 21: 143-149. https://doi.org/10.1016/j.pt.2005.01.003
  6. Wilson RA, Coulson PS. Schistosome vaccines: a critical appraisal. Mem Inst Oswaldo Cruz 2006; 101: S13-20. https://doi.org/10.1590/S0074-02762006000900004
  7. Hillyer GV. Fasciola antigens as vaccines against fascioliasis and schistosomiasis. J Helminthol 2005; 79: 241-247. https://doi.org/10.1079/JOH2005304
  8. Aban JL, Ramajo V, Arellano JL, Oleaga A, Hillyer GV, Muro A. A fatty acid binding protein from Fasciola hepatica induced protection in C57/BL mice from challenge infection with Schistosoma bovis. Vet Parasitol 1999; 83: 107-121. https://doi.org/10.1016/S0304-4017(99)00053-9
  9. Sirisriro A, Grams R, Vichasri-Grams S, Ardseungneon P, Pankao V, Meepool A, Chaithirayanon K, Viyanant V, Tan-Ariya P, Upatham ES, Sobhon P. Production and characterization of a monoclonal antibody against recombinant fatty acid binding protein of Fasciola gigantica. Vet Parasitol 2002; 105: 119-129. https://doi.org/10.1016/S0304-4017(02)00007-9
  10. Nessim NG, Hassan SI, William S, el-Baz H. Effect of the broad spectrum anthelmintic drug flubendazole upon Schistosoma mansoni experimentally infected mice. Arzneimittelforschung 2000; 50: 1129-1133.
  11. Timanova A, Müller S, Marti T, Bankov I, Walter RD. Ascaridia galli fatty acid-binding protein, a member of the nematode polyprotein allergens family. Eur J Biochem 1999; 261: 569-576. https://doi.org/10.1046/j.1432-1327.1999.00328.x
  12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685. https://doi.org/10.1038/227680a0
  13. Duvall RH, DeWitt WB. An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 1967; 16: 483-486. https://doi.org/10.4269/ajtmh.1967.16.483
  14. Cheever AW. Conditions affecting the accuracy of potassium hydroxide digestion techniques for counting Schistosoma mansoni eggs in tissues. Bull World Health Organ 1968; 39: 328-331.
  15. Pellegrino J, Oliveira CA, Faria J, Cunha AS. New approach to the screening of drugs in experimental Schistosomiasis mansoni in mice. Am J Trop Med Hyg 1962; 11: 201-215. https://doi.org/10.4269/ajtmh.1962.11.201
  16. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971; 8: 871-874. https://doi.org/10.1016/0019-2791(71)90454-X
  17. von Lichtenberg. Host response to eggs of S. mansoni. I. Granuloma formation in the unsensitized laboratory mouse. Am J Pathol 1962; 41: 711-731.
  18. Cherfas J. New hope for vaccine against schistosomiasis. Science 1991; 251: 630-631. https://doi.org/10.1126/science.1992516
  19. McManus DP. A vaccine against Asian schistosomiasis: the story unfolds. Int J Parasitol 2000; 30: 265-271. https://doi.org/10.1016/S0020-7519(99)00200-3
  20. Hillyer GV. Comparison of purified 12 kDa and recombinant 15 kDa Fasciola hepatica antigens related to a Schistosoma mansoni fatty acid binding protein. Mem Inst Oswaldo Cruz 1995; 90: 249-253. https://doi.org/10.1590/S0074-02761995000200021
  21. Janecharut T, Kitikoon V, Usawattanakul W, Sornmani S. Investigation on immunity induced by Schistosoma spindale against S. mekongi in experimental mice. Southeast Asian J Trop Med Public Health 1988; 19: 123-129.
  22. Agnew AM, Murare HM, Doenhoff MJ. Specific cross-protection between Schistosoma bovis and S. haematobium induced by highly irradiated infections in mice. Parasite Immunol 1989; 11: 341-349. https://doi.org/10.1111/j.1365-3024.1989.tb00672.x
  23. Dean DA, Mangold BL, Harrison RA, Ricciardone MD. Homologous and heterologous protective immunity to Egyptian strains of Schistosoma mansoni and S. haematobium induced by ultraviolet-irradiated cercariae. Parasite Immunol 1996; 18: 403-410. https://doi.org/10.1046/j.1365-3024.1996.d01-129.x
  24. Rabia I, Ali E, Hassan E, Salah F, El-Dafrawy T. Intraperitoneal injection of Echinostome antigens confers resistance to schistosomal infection in murine model. New Egypt J Med 2007; 36: 25-31.
  25. Siles-Lucas M, Uribe N, Lopez-Aban J, Vicente B, Orfao A, Nogal-Ruiz JJ, Feliciano AS, Muro A. The Schistosoma bovis Sb14-3-3zeta recombinant protein cross-protects against Schistosoma mansoni in BALB/c mice. Vaccine 2007; 25: 7217-7223. https://doi.org/10.1016/j.vaccine.2007.07.021
  26. Hamed MA. Excretory-secretory product of Fasciola hepatica worm protects against Schistosoma mansoni infection in mice. Indian J Exp Biol 2006; 44: 554-561.
  27. Snapper CM, Mond JJ. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993; 14: 15-17. https://doi.org/10.1016/0167-5699(93)90318-F
  28. Pfeifhofer C, Gruber T, Letschka T, Thuille N, Lutz-Nicoladoni C, Hermann-Kleiter N, Braun U, Leitges M, Baier G. Defective IgG2a/2b class switching in PKC alpha-/- mice. J Immunol 2006; 176: 6004-6011. https://doi.org/10.4049/jimmunol.176.10.6004
  29. Nascimento E, Leao IC, Pereira VR, Gomes YM, Chikhlikar P, August T, Marques E, Lucena-Silva N. Protective immunity of single and multi-antigen DNA vaccines against schistosomiasis. Mem Inst Oswaldo Cruz 2002; 97: S105-109.
  30. Dupre, Herv M, Schacht AM, Capron A, Riveau G. Control of schistosomiasis pathology by combination of Sm28GST DNA immunization and praziquantel treatment. J Infect Dis 1999; 180: 454-463. https://doi.org/10.1086/314875
  31. Ramos HR, Miyasato PA, Ramos CR, de Mattos Arêas AP, Kawano T, Ho PL. A genetic fusion between Sm14 and CTB does not reduce Schistosoma mansoni worm burden on intranasally immunized BALB/c mice. J Vaccines Vaccin 2010; 1: 111.
  32. Pearce EJ, James SL, Hieny S, Lanar DE, Sher A. Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc Natl Acad Sci U S A 1988; 85: 5678-5682. https://doi.org/10.1073/pnas.85.15.5678
  33. Cardoso FC, Macedo GC, Gava E, Kitten GT, Mati VL, de Melo AL, Caliari MV, Almeida GT, Venancio TM, Verjovski-Almeida S, Oliveira SC. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2008; 2: e308. https://doi.org/10.1371/journal.pntd.0000308
  34. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, Lloyd JD, Pompa J, Villalovos RM, Paz M. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21: 2882-2889. https://doi.org/10.1016/S0264-410X(03)00159-2

Cited by

  1. Development of the Brazilian Anti Schistosomiasis Vaccine Based on the Recombinant Fatty Acid Binding Protein Sm14 Plus GLA-SE Adjuvant vol.6, pp.None, 2015, https://doi.org/10.3389/fimmu.2015.00218
  2. Protection against Schistosoma mansoni infection using a Fasciola hepatica -derived fatty acid binding protein from different delivery systems vol.9, pp.1, 2012, https://doi.org/10.1186/s13071-016-1500-y
  3. Effect of regulatory T cells on the efficacy of the fatty acid-binding protein vaccine against Schistosoma japonicum vol.118, pp.2, 2012, https://doi.org/10.1007/s00436-018-6186-y